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but no pairwise comparisons were statistically significant. CONCLUSIONS: The 
analysis demonstrates that many of the treatments are efficacious in controlling 
symptoms, although side effects resulting from treatment should be considered; 
weight gain is commonly observed, and treatment discontinuation due to adverse 
events is variable between studies. The lack of high-quality studies in this popula-
tion highlights a need for further research.
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OBJECTIVES: To assess relative efficacy and tolerability of vortioxetine versus other 
antidepressants in patients with major depressive disorder (MDD) who experience 
inadequate response after treatment with selective serotonin reuptake inhibitors 
(SSRIs) or serotonin–norepinephrine reuptake inhibitors (SNRIs). METHODS: A 
systematic literature review identified 27 switch studies, three of which (REVIVE, 
Kasper 2013 and STAR*D) contributed to the relevant network for quantitative 
assessment, based on remission rate and withdrawal rate due to adverse events 
(AEs). Switch treatments compared to vortioxetine in the analysis were agomel-
atine, sertraline, venlafaxine XR and bupropion SR, commonly used in clinical 
practice. Simple adjusted indirect comparisons using Bucher’s method were also 
conducted, in line with guidelines from EUnetHTA. RESULTS: Direct analysis of 
remission rates based on the REVIVE study showed vortioxetine had a signifi-
cantly higher remission rate (relative difference: -11.0% [95% CI: -19.4; -2.6]) than 
agomelatine. Indirect comparisons revealed that vortioxetine had numerically 
higher remission rates than sertraline (relative difference: -14.4%, [95% CI: -29.9; 
1.1]), venlafaxine (relative difference: -7.20%, [95% CI: -24.3; 9.9]), and bupropion 
(relative difference: -10.70%, [95% CI: -27.8; 6.4]). Rate of withdrawals due to AE 
was numerically lower with vortioxetine than agomelatine (relative difference: 
3.6%, [95% CI: -1.1; 8.3]). Indirect comparison showed that withdrawal rates due 
to AE were significantly lower for vortioxetine than sertraline (relative difference: 
12.1%, [95% CI: 3.1; 21.1]), venlafaxine (relative difference: 12.3%, [95% CI: 0.8; 23.8]), 
and bupropion (relative difference: 18.3%, [95% CI: 6.4; 30.1]). CONCLUSIONS: The 
evidence supporting treatment strategies for patients with MDD with inadequate 
response to SSRI or SNRI is limited. This study demonstrates that remission rates 
for vortioxetine are numerically higher than other antidepressants widely used 
in clinical practice. Vortioxetine is a well-tolerated treatment, showing statisti-
cally lower withdrawal rates due to AE in patients with MDD with an inadequate 
response to prior SSRI or SNRI monotherapy.
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OBJECTIVES: To assess the effects of the reformulation of OxyContin (ERO) with 
physicochemical abuse-deterrent properties that are intended to make tablets 
harder to crush, dissolve or chew on rates of abuse of ERO compared to other opioids 
using 6 national surveillance systems at 3 years after reformulation. METHODS: 
Data from 6 surveillance systems were examined: 1) National Poison Data System 
(NPDS), 2) RADARS Poison Center(PC) Program, 3) NAVIPPRO ASI-MV System assess-
ing individuals in substance abuse treatment, 4) RADARS Drug Diversion program 
using law enforcement officials’ surveillance,5) doctor-shopping using the IMS 
prescription database, and 6) Spontaneous adverse event reports of fatalities to 
the manufacturer. Changes in abuse rates were compared from the year before (Jul 
2009-Jun 2010) to 3 years after (January 2011 - June 2013) reformulation of ERO. The 
period from July to December 2010 was considered a transition period. Comparator 
opioid groups were: a) other extended-release opioid analgesic tablets and capsules 
(excluding ERO, methadone and transdermal patches) and b) immediate-release 
oxycodone (single-entity and combination products). RESULTS: Compared to the 
year prior to reformulation, there were large decreases in abuse rates of ERO in 
all 6 surveillance systems in the 3 years after ERO reformulation: 55% decrease 
(p< 0.001) in NPDS, 55% decrease (p< 0.001) in RADARS PC, 48% decrease (p< 0.001) in 
NAVIPPRO System assessing individuals in substance abuse treatment, 61% decrease 
(p< 0.001) in RADARS Drug Diversion program using law enforcement officials’ sur-
veillance, 50% decrease in doctor shopping rates for ERO nationally. Reductions 
for ERO were significantly greater than changes for the two comparator opioid 
groups. Spontaneously reported overdose fatalities reported to the manufacturer 
decreased 87% by the 3rdyear, while non-fatal ERO reports did not decrease post-
reformulation. CONCLUSIONS: These findings indicate that abuse of ERO declined 
after its reformulation and these declines have persisted through three years post-
reformulation. Additional follow-up is ongoing.
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OBJECTIVES: Despite different pharmacological strategies in the management of 
depression, many patients experience inadequate response to treatment in clinical 
practice. A systematic review was carried out to perform a qualitative assessment 
of studies examining different antidepressant monotherapies in patients with 
major depressive disorder (MDD), and an inadequate response to prior selective-
serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor 
(SNRI) therapy. METHODS: MEDLINE®, Embase®, Cochrane, CDSR, and PsychINFO® 
databases, and clinical trial registries were searched from January 1980 to 27 March 
2014. The review included trials in patients with MDD with inadequate response to 
SSRIs/SNRIs. Included studies underwent a two-stage screening process conducted 
by two independent reviewers, with discrepancies reconciled by a third independent 
reviewer. Data were extracted by a single reviewer with quality check performed by 
another, and multiple publications were linked. The quality of included studies was 
critically appraised based on recommendations from national guidelines. RESULTS: 
The database search retrieved 11 953 citations, of which 27 randomized controlled 
trials from 54 publications met the inclusion criteria. The switch interventions 
assessed included: SSRIs, SNRIs, and other non-SSRI/SNRI antidepressants such as 
monoamine oxidase inhibitors, tricyclic antidepressants, tetracyclic antidepres-
sants, with a few studies comparing different antidepressants in switch therapy. 
The evidence varied in terms of: type of treatment, study duration (ranging from 
2 weeks to 14 weeks), depression scale, sample size (< 100 to > 500 patients), prior 
therapy, and definition of inadequate response. Generally, the mean age of included 
patients was comparable (44 years to 48 years). Overall, few of the included studies 
were deemed to be of good quality. CONCLUSIONS: A comprehensive overview of 
switch studies assessing antidepressant monotherapies in prior SSRI/SNRI non-
responding patients found an overall low strength of evidence for studies evaluating 
these monotherapies. Limited clinical data have been retrieved but give the pos-
sibility to perform further quantitative evaluations.
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OBJECTIVES: Paroxetine has strong anticholinergic properties and may lead to 
adverse cognitive outcomes. This study compared paroxetine and other selective 
serotonin reuptake inhibitors (SSRIs) with respect to cognition among elderly nurs-
ing home residents with depression. METHODS: A propensity score-adjusted retro-
spective cohort study was conducted using data from Medicare Part D claims and 
Minimum Data Set (MDS) from 2007-2010. New users of paroxetine and other SSRIs 
were followed until they reached the end of the follow up period (1 year), switched 
to a different antidepressant class, used psychotherapy, had a gap or more than 15 
days in the use of index antidepressant class, whichever occurred earlier. Exposure 
to SSRIs formed the main independent variable. The main outcome variable was 
cognition and it was measured using the MDS Cognition Scale. Repeated measures 
mixed model was used to examine the effect of SSRIs use on cognition, with use of 
other SSRIs as the reference category. Other covariates in the final model included 
propensity scores and their interaction terms. RESULTS: The study cohort consisted 
of 1,081 elderly nursing home residents. Of these, 63 (5.83%) received paroxetine 
and 1,018 received other SSRIs (94.17%). After adjusting for propensity scores, the 
repeated measure mixed model did not find any statistically significant difference in 
cognition with the use of paroxetine (β = -0.25 [95% CI, -0.84, 0.35]) when compared 
to other SSRIs. Results from the sensitivity analysis were consistent with the main 
findings. CONCLUSIONS: This study did not find any significant effect of paroxetine 
on cognition when compared to other SSRIs in elderly nursing home residents with 
depression. Long term studies are needed to evaluate comparative safety profiles 
of SSRIs in this vulnerable population.
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self-RePoRted dePRession and PRescRiPtion of antidePRessants; does 
gendeR MatteR?
Thunander Sundbom L.1, Bingefors K.2, Isacson D.2
1University of Gävle, Gävle, Sweden, 2Uppsala University, Uppsala, Sweden
OBJECTIVES: Women are diagnosed with depression twice as often as men. 
Concerning self-reported depression though, gender differences are not that dis-
tinct. Prescription of antidepressants (ADs) has increased considerably the past 
decades, especially for women. This study aimed to examine gender differences in 
self-reported depression and the relation to prescribed ADs and also in the prescrip-
tion of various types of ADs. METHODS: Data from the population-based cross-sec-
tional survey “Public Health in Sweden 2012” was used (n= 16,000 aged 18-84 years, 
response rate 49.3%). Symptoms of depression were measured with the Hospital 
Anxiety Depression Scale (HADS, cut-off score ≥ 8). Self-reported use of ADs two 
weeks prior to receiving the questionnaire was supplemented with prescription data 
(ATC-codes) from the national Swedish Prescribed Drug Register. RESULTS: Men and 
women reported depression to similar extent (men 12.3%, women 11.2%). However, 
women were more often prescribed ADs compared to men (men 3.7%, women 6.8%; 
p< 0.0001). Nine per cent of all women in the study population reported depression 
but had no AD treatment, 2.1% reporting depression and used ADs, and 4.7% used 
ADs but reported no depression. The corresponding figures for men were 10.8%, 1.5% 
and 2.2% (p< 0.0001). Selective serotonin reuptake inhibitors (SSRIs, N06AB) were the 
most commonly prescribed ADs for both men (74.8%) and women (79.2%). As for the 
SSRIs, no statistical significant gender difference was found for the tricyclic antide-
pressants (TCAs, N06AA; men 9.5%, women 6.7%). However, men were prescribed 
“Other ADs” (N06AX) significantly more often than women (men 43.3%, women 
29.2%; p< 0.005). CONCLUSIONS: Although women and men reported depression 
to similar extent, women were prescribed ADs almost twice as often as men. Also, 
women used ADs without being currently depressed more often than men. Further, 
men were prescribed “Other ADs” more frequently than women.
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OBJECTIVES: To examine incidence, prevalence and mortality rates among opioid-
dependent patients in the U.S. Medicare population. METHODS: A study was per-
formed for the period from January 1, 2008 through December 31, 2012 to determine 
the prevalence, incidence and mortality rates among opioid-dependent patients 
(International Classification of Diseases, 9th Revision, Clinical Modification diag-
nosis codes 304.0x and 304.7x) in the U.S. Medicare population. Patients who had 
continuous fee-for-service Medicare health plan enrollment for the calendar year 
and at least 2 years prior were selected for the study. Age- and gender-adjusted 
opioid dependence prevalence and incidence rates were calculated via direct stand-
ardization to the U.S. population age ≥ 65 years in 2010 using gender-specific age 
groups. RESULTS: The annual adjusted prevalence of opioid-dependent patients 
increased from 0.06% in 2008 to 0.35% in 2012. Incidence rates increased from 0.06% 
in 2008 to 0.10% in 2012. Prevalence rates were higher among women than men every 
year during the study period. Patients age 65-69 years had the highest prevalence 
rates during 2008 (0.09%), 2009 (0.16%), 2010 (0.22%) and 2011 (0.32%). However, in 
2012, patients who were age 70-74 years had the highest prevalence rates (0.43%). 
North American Natives had the highest prevalence of opioid dependence compared 
to all other races. The highest incidence of opioid dependence was observed in 
Nevada in 2008 (221.9 per 100,000 person-years) and 2012 (222.1 per 100,000 person-
years). The 30-day and 1-year mortality rates decreased by 10.5% (3.8 to 3.4 per 1,000 
person-years) and 25.4% (17.3 to 12.9 per 1,000 person-years), respectively, from 2008 
to 2012. CONCLUSIONS: Opioid dependence incidence and prevalence decreased 
from 2008 to 2012; however, opioid dependence-related mortality rates increased.
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OBJECTIVES: Given the lack of research on this in China, treatment guidelines for 
major depressive disorder (MDD) have been adapted based on Western guidelines. 
This study assessed health outcomes of MDD-diagnosed and MDD-undiagnosed 
vs. non-depressed respondents in urban China. METHODS: Data were obtained 
from the 2012 China National Health and Wellness Survey, a mixed-methodology, 
internet-based, nationwide survey of adults (18+ years) stratified by gender and 
age to represent the demographic composition of urban China. Respondents self-
reporting physician diagnosis of depression and screening positive for MDD based 
on Patient Health Questionnaire-9 (PHQ-9) scores (n= 97), plus those screening 
positive for MDD but undiagnosed and not experiencing depression (n= 1,005) were 
compared with non-depressed respondents (n= 17,022). Undiagnosed respondents 
were further compared across MDD severity levels (moderate, moderately severe, 
severe). Outcomes included: SF-36v2-based mental (MCS) and physical (PCS) 
component summary scores and SF-6D health utilities; Work Productivity and 
Activity Impairment questionnaire-based metrics; and resource utilization (past 
six months). Regression models assessed health outcomes as a function of MDD, 
controlling for demographics and comorbidities. RESULTS: MDD prevalence was 
6.0%, with 8.3% of MDD-screened respondents diagnosed with depression, among 
whom 51.5% currently used prescription medication for depression. After adjust-
ment, diagnosed and undiagnosed MDD respondents had lower health utilities 
and PCS and MCS (diagnosed-MDD: 32.8; undiagnosed-MDD: 37.1; non-depressed: 
46.9) scores, plus greater absenteeism, presenteeism, overall work impairment 
(diagnosed-MDD: 47.1%; undiagnosed-MDD: 46.4%; non-depressed: 23.0%), activity 
impairment, emergency room visits (diagnosed-MDD: 0.95; undiagnosed-MDD: 0.72; 
non-depressed: 0.32), hospitalizations, and traditional provider visits, compared 
with non-depressed respondents, all p< 0.01. Severe vs. moderate undiagnosed-
MDD respondents had lower MCS and PCS and 1.4 times as many provider visits 
(all p< 0.05). CONCLUSIONS: Over 90% of MDD-screened respondents were undiag-
nosed. MDD sufferers in urban China may be under-diagnosed and undertreated. 
Awareness and better access to treatments may help alleviate the burden associ-
ated with MDD.
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OBJECTIVES: To examine incidence and prevalence rates among alcohol-dependent 
patients in the U.S. Medicare population. METHODS: A prospective study was per-
formed from 01JAN2008 through 31DEC2012 to determine the prevalence and inci-
dence of patients diagnosed with alcohol dependence (International Classification 
of Diseases, 9th Revision, Clinical Modification diagnosis code 303) in the U.S. 
Medicare population. Patients were required to have continuous enrollment in a 
fee-for-service Medicare health plan during the calendar year and at least 2 years 
prior. The age- and gender-adjusted prevalence and incidence (overall and age- 
and gender-specific) rates of alcohol-dependent patients were calculated by direct 
standardization to the U.S. population age ≥ 65 years in 2010. RESULTS: The annual 
adjusted overall prevalence rate increased from 0.30% in 2008 to 1.05% in 2012, 
whereas the annual overall incidence rate decreased from 0.30% in 2008 to 0.20% 
in 2012. Alcohol dependence prevalence and incidence rates were higher among 
men than women every year. Patients age 65-69 years had the highest prevalence 
rates during 2008 (0.43%) and 2009 (0.63%), whereas in 2010 (0.82%), 2011 (1.14%) and 
2012 (1.43%), patients age 70-74 years had the highest prevalence rates. Prevalence 
rates grew steadily among all age groups from 2008 to 2012. The highest alcohol 
dependence incidence rate was observed in the Virgin Islands (917.6 per 100,000 
person-years) in 2008, whereas in 2012, Wyoming (409.3 per 100,000 person-years) 
had the highest incidence rate. CONCLUSIONS: Increasing prevalence and decreas-
ing incidence of alcohol dependence was observed from 2008 to 2012. In addition, 
men were more likely to have alcohol dependence than women.
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OBJECTIVES: Estimating the trends in the prevalence of dementia has been a chal-
lenge because it has been relying on self-reported information in the national repre-
sentative surveys or based on diagnosis alone in community-based studies. With the 
aging of population, it is still unclear if there were any time trends in the prevalence 
of dementia. The objective of this study is to investigate the national trends in the 
prevalence of dementia using combined sources of information. METHODS: A trend 
analysis was performed using data from the Medicare Current Beneficiary Survey 
(MCBS) 2001-2010. The study sample consisted of Medicare beneficiaries aged 65 
or older. Dementia was determined based on the self-reported diagnosis, or having 
diagnosis codes in Medicare claims, or utilization of dementia-targeted prescription 
medications identified in self/proxy’s report. Cross-sectional weights were used to 
adjust for the complex survey design of MCBS. RESULTS: The prevalence of demen-
tia increased approximately 20% from 8.3% in 2001 to 10.4% in 2010 (p< .001). This 
increasing time trends were largely explained by the increase in the prevalence of 
dementia in the community setting. The prevalence remained stable in the long-
term care facilities, but increased from 4.8% to 7.3% in the community settings over 
time. We also observed the increase in the prevalence of dementia across age, sex 
and race groups. The prevalence of dementia was lower among Medicare beneficiar-
ies aged 65-75 years vs. 75 years and older, among whites vs. blacks and Hispanics, 
and in women vs. men. CONCLUSIONS: Our findings suggested the increase in the 
prevalence of dementia existing among elderly from 2001 to 2010.
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OBJECTIVES: Prenatal alcohol ingestion predisposes fetus to long term neuro-
developmental defects, yet limited studies have been done to assess its prevalence 
in Ghana. This study determined the prevalence and factors associated with the 
practice in the coastal town of Accra. METHODS: A cross sectional analytic study 
was conducted. Two hundred and forty nine pregnant women were randomly sam-
pled in James town Accra. Structured questionnaires administered to participants. 
Information gathered include prenatal alcohol consumption status, socio-economic 
status, knowledge on effects of prenatal alcohol ingestion, types of alcoholic 
beverages ingested and reasons for ingestion. Data was managed in EPI INFO 7, 
using prevalence Odds Ratio to estimate association between variables. RESULTS: 
Prevalence of Prenatal alcohol consumption was 47.4 percent. The age ranged 18 
– 48 with mean, median and modal ages as 25.7 ± 6.7, 25 and 18 years respectively. 
Among prenatal alcohol consumers, age ranged 18-48; mean, median and mode 
were 25.9 ± 6.6, 25 and 18 years respectively. The monthly income among respond-
ents ranged GHS 0.00 – 2000 (USD 0.00-625) with 120.00 (USD 37.50) as median 
income and modal monthly income 0.00 (USD 0.00). The types of alcoholic bever-
ages ingested included Beer (58%), Pito (16.7%), and Gin (10.8%). Bivariate analysis 
showed that participants who belong to religious group other than Christianity 
and Muslim (OR= 10.9 CI 2.47-48.01), having less than Junior High School education 
(OR= 2.07 CI 1.25-3.44) was associated with prenatal alcohol ingestion, however age 
(OR= 1.08 CI 0.65-1.79), having spouse or not (OR= 1.00), employment status (OR= 1.68 
CI 0.90-3.14) were not significantly associated with alcohol consumption. Reasons 
for pre-natal alcohol ingestions includes socialization or peer pressure (31.7 per-
cent), as appetizer (19.2 percent), to relieve stress (12.5 percent) and for happiness 
(10.8 percent). CONCLUSIONS: Prevalence of prenatal alcohol ingestion is high and 
associated with inadequate information. It is imperative to develop health promo-
tion strategy to address it.
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OBJECTIVES: Depression is one of the most common mental disorders in the general 
population, and may be of particular importance in Japan, which has the 7th highest 
suicide rate globally. However, depressed patients are underdiagnosed and under-
treated in the general population. We aimed to evaluate the prevalence of depression 
in the general Japanese population and the relationship of socioeconomic status 
(SES) factors with that disease. METHODS: This was a cross-sectional study. We 
used a population weighted random sample from a nationally representative panel 
of adults (≥ 20 years). A baseline questionnaire was used to capture demographic 
data, lifestyle habits, and SES parameters including family income, education level, 
and type of family. Depression was defined as a score of > 9 on the Patient Health 
Questionnaire (PHQ-9). RESULTS: 3,722 people were included in this study (mean 
age, 52 years old (SD, 18); 1,758 (47.2%) men.) The prevalence of depression was 27.1% 
(n= 1,007), among whom 55 (5.5%) were already diagnosed with depression and 605 
(60%) was women. Using multivariate logistic regression, for men, the risk factors 
for depression included lower educational attainment (OR: 1.3), low family annual 
income (< $30,000, OR: 2.3), and past history of depression (OR: 3.8). On the other 
hand, for women, they included obesity (BMI ≥ 25 kg/m2, OR: 1.5) and past history of 
depression (OR: 5.4) and SES was not associated with depression. CONCLUSIONS: 
Depressive disorders are highly prevalent in the Japanese general population. SES 
including education level and family annual income are not associated with women 
depression but with men depression.
